Prelude Capital Management, LLC Next Cure, Inc. Transaction History

Prelude Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$4.76 - $6.24 $87,108 - $114,192	-18,300 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$5.7 - $9.1 $245,709 - $392,273	-43,107 Reduced 70.2%	18,300 $110,000
Q3 2021 Nov 15, 2021	BUY	$6.74 - $8.02 $413,883 - $492,484	61,407 New	61,407 $414,000
Q4 2020 Feb 16, 2021	SELL	$9.47 - $12.43 $10,417 - $13,673	-1,100 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$8.15 - $21.17 $8,965 - $23,287	1,100 New	1,100 $10,000

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $36.4M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.